Chasity D Andrews1, Walid Heneine. 1. aAaron Diamond AIDS Research Center, The Rockefeller University, New York, New York bLaboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV, Hepatitis, STD, and Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
PURPOSE OF REVIEW: Preexposure prophylaxis (PrEP) with daily Truvada has demonstrated clinical efficacy against HIV-1 acquisition that correlates with high adherence. Long-acting antiretroviral drugs offer an alternative to daily regimens and may improve PrEP adherence. This review summarizes the preclinical nonhuman primate studies for evaluating the efficacy of cabotegravir long-acting as PrEP and the ongoing phase 2a studies assessing safety, tolerability, and acceptability of cabotegravir long-acting. RECENT FINDINGS: Cabotegravir is an HIV-1 integrase strand transfer inhibitor with intrinsic properties that permit its formulation as a long-acting injectable suspension. In clinical evaluation, cabotegravir long-acting has a half-life that permits infrequent dosing, possibly once every 3 months. In validated macaque models, cabotegravir long-acting demonstrated high protection against both rectal and vaginal transmission at clinically achievable drug concentrations. SUMMARY: PrEP, after approval of Truvada, continues to evolve to address adherence limitations of daily dosing. As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits quarterly dosing and demonstrated high efficacy in macaque models supporting dose selection and clinical development. Clinical studies have confirmed dose selection in phase 2a trials with cabotegravir long-acting to ultimately lead to phase 2b/3 PrEP efficacy trials.
PURPOSE OF REVIEW: Preexposure prophylaxis (PrEP) with daily Truvada has demonstrated clinical efficacy against HIV-1 acquisition that correlates with high adherence. Long-acting antiretroviral drugs offer an alternative to daily regimens and may improve PrEP adherence. This review summarizes the preclinical nonhuman primate studies for evaluating the efficacy of cabotegravir long-acting as PrEP and the ongoing phase 2a studies assessing safety, tolerability, and acceptability of cabotegravir long-acting. RECENT FINDINGS:Cabotegravir is an HIV-1 integrase strand transfer inhibitor with intrinsic properties that permit its formulation as a long-acting injectable suspension. In clinical evaluation, cabotegravir long-acting has a half-life that permits infrequent dosing, possibly once every 3 months. In validated macaque models, cabotegravir long-acting demonstrated high protection against both rectal and vaginal transmission at clinically achievable drug concentrations. SUMMARY: PrEP, after approval of Truvada, continues to evolve to address adherence limitations of daily dosing. As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits quarterly dosing and demonstrated high efficacy in macaque models supporting dose selection and clinical development. Clinical studies have confirmed dose selection in phase 2a trials with cabotegravir long-acting to ultimately lead to phase 2b/3 PrEP efficacy trials.
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Nicole Luisi; Jeremy Grey; Travis Sanchez; Carlos Del Rio; John L Peterson; Paula M Frew; Patrick S Sullivan; Colleen F Kelley Journal: Int J STD AIDS Date: 2016-10-20 Impact factor: 1.359
Authors: William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai Journal: Drug Deliv Transl Res Date: 2017-12 Impact factor: 4.617
Authors: D Kerrigan; A Mantsios; R Grant; M Markowitz; P Defechereux; M La Mar; S W Beckham; P Hammond; D Margolis; M Murray Journal: AIDS Behav Date: 2018-11
Authors: Martina Kovarova; Michael D Swanson; Rosa I Sanchez; Caroline E Baker; Justin Steve; Rae Ann Spagnuolo; Bonnie J Howell; Daria J Hazuda; J Victor Garcia Journal: J Antimicrob Chemother Date: 2016-03-21 Impact factor: 5.790
Authors: Christine Tagliaferri Rael; Michelle Martinez; Rebecca Giguere; Walter Bockting; Caitlin MacCrate; Will Mellman; Pablo Valente; George J Greene; Susan G Sherman; Katherine H A Footer; Richard T D'Aquila; Alex Carballo-Diéguez; Thomas J Hope Journal: AIDS Behav Date: 2020-05